JordanaCohen University of PennsylvaniaUnited States

JordanaCohen
Dr. Cohen is an Associate Professor of Medicine and Epidemiology in the Renal-Electrolyte and Hypertension Division and Department of Biostatistics, Epidemiology and Informatics at the University of Pennsylvania, Philadelphia, PA, USA. She leads a portfolio of research projects that 1) examine physiology-driven pharmacologic effects of antihypertensive medications in complex and high-risk disease states and 2) seek novel strategies to improve blood pressure measurement and mitigate target organ effects of hypertension. She is Chair of the AHA’s Hypertension Science Committee and Co-Chair of the Chronic Renal Insufficiency Cohort Blood Pressure Working Group and the AMA’s Blood Pressure Validated Device Listing.
Institution

Day 3 - Tuesday April 16, 2024

Time Session
9 a.m.
10:30 a.m.
CarlosSchreck Chairperson carlos.schreck@gmail.comHospital Italiano de Buenos Aires- NephrologyArgentina
KellyHaughton Chairperson kidneydoctorpanama@gmail.comSLANH, PanamaPanama
  • Why Are Fewer Than I% Of Hypertensive Patients Ever Screened For Primary Aldosteronism?
    John Funder Speaker John.Funder@hudson.org.auThe Hudson Institute of Medical Research Clayton 3168 Victoria Australia; Monash University, Clayton 3600 Victoria AustraliaAustralia
  • Aldosterone and Disease
    JordanaCohen Speaker jco@pennmedicine.upenn.eduUniversity of PennsylvaniaUnited States
  • New Trials Using Aldosterone Synthese Blockade
    MichelAzizi Speaker michel.azizi@aphp.frUniversité Paris Cité, Hypertension department, HôFrance
  • Targeting MR for Heart and Kidney Protection
    HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands
  • Q and A
Hall E
12:30 p.m.
1:30 p.m.
MarceloOrías Chairperson marcelo.orias@gmail.comArgentina
MarkSarnak Chairperson msarnak@tuftsmedicalcenter.orgTufts Medical CenterUnited States
  • Hot Debate in CKD Hypertension Management: Targeting Systolic BP Below 120? - PROS
    TaraChang Speaker tichang@stanford.eduStanford UniversityUnited States
  • Hot Debate in CKD Hypertension Management: Targeting Systolic BP Below 120? - CONS
    JordanaCohen Speaker jco@pennmedicine.upenn.eduUniversity of PennsylvaniaUnited States
Hall A